Catalyst Capital Advisors
MYOK

Catalyst Capital Advisors’s MyoKardia, Inc. Common Stock MYOK Stock Holding History

Catalyst Capital Advisors’s Portfolio MYOK Stock Details MYOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-95
Closed -$5K – 460
2019
Q3 		$5K Buy
+95
New +$5.05K ﹤0.01% 408

Other funds holding MYOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Catalyst Capital Advisors's MYOK Position: Q4 2019 in Review

Catalyst Capital Advisors sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2019, closing a stake of 95 shares — an estimated $5K sold.

Catalyst Capital Advisors first reported a position in MYOK in Q3 2019 and held it in 1 quarter. The position peaked at $5K in Q3 2019. 178 funds tracked by Wall St. Rank hold MYOK as of Q4 2019.

  • Catalyst Capital Advisors reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 95 MyoKardia, Inc. Common Stock shares in Q4 2019, an estimated $5K.
  • Catalyst Capital Advisors first reported a position in MyoKardia, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's MyoKardia, Inc. Common Stock position peaked at $5K in Q3 2019.
  • 178 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2019.

Based on Catalyst Capital Advisors's 13F filing for Q4 2019, filed 6 Feb 2020.